Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B
Haemophilia · 2024
DOI: 10.1111/hae.14882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2024. Verfasst von Robert Klamroth und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department for Internal Medicine, Haemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany. Hauptthemen laut MEDLINE: Factor IX, Hemophilia B. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring.
Abstract (Originalsprache)
Introduction
Etranacogene dezaparvovec gene therapy for haemophilia B demonstrated superior efficacy at 24 months in reducing bleeds versus a ≥6‐month lead‐in period of prophylaxis with FIX products in the phase 3 trial, HOPE‐B. In the absence of head‐to‐head comparisons of etranacogene dezaparvovec versus FIX products, indirect treatment comparisons (ITC) can be used.
Aim
To compare the efficacy of etranacogene dezaparvovec versus rIX‐FP, rFIXFc and N9‐GP using ITC, and support HOPE‐B results.
Methods
Data were leveraged from Phase 3 pivotal trials: HOPE‐B, PROLONG‐9FP, B‐LONG and Paradigm 2. Annualised bleeding rates (ABR), spontaneous (AsBR) and joint (AjBR) bleeding rates, percentage of patients with no bleeds, and FIX consumption were assessed using inverse probability of treatment weighting and matching adjusted indirect comparisons.
Results
Etranacogene dezaparvovec demonstrated statistically significantly lower bleeding rates versus all comparators. Rate ratios for ABR, AsBR and AjBR versus rIX‐FP were 0.19 ( p < .0001), 0.08 ( p < .0001) and 0.09 ( p < .0001), respectively. Rate ratios for ABR, AsBR and AjBR versus rFIXFc were 0.14 ( p < .0001), 0.13 ( p = .0083) and 0.15 ( p = .0111), respectively. Rate ratios for ABR and AsBR, versus N9‐GP were 0.24 ( p = .0231) and 0.13 ( p = .0071), respectively. Etranacogene dezaparvovec demonstrated significantly higher percentage of patients with no bleeds versus rIX‐FP and rFIXFc; odds ratios: 17.60 ( p < .0001) and 5.65 ( p = .0037), respectively. Etranacogene dezaparvovec resulted in significantly lower FIX consumption than all comparators.
Conclusions
ITC suggests that etranacogene dezaparvovec offers patients with haemophilia B (≤2% of normal FIX expression) a single dose treatment that can significantly reduce bleeding rates and eliminate routine infusions associated with FIX therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Internal Medicine, Haemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
- Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Nordrhein-Westfalen, Germany.
- EVERSANA, Ontario, Canada.
- Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, UK.
- CSL Behring, King of Prussia, Pennsylvania, USA.
ORCID-Profile: Robert Klamroth, Songkai Yan
Förderung
- CSL Behring
Zitieren
APA
Klamroth, R., Bonner, A., Gomez, K., Monahan, P. E., Szafranski, K., Zhang, X., Walsh, S., Wang, D., & Yan, S. (2024). Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B. Haemophilia. https://doi.org/10.1111/hae.14882
Vancouver
Klamroth R, Bonner A, Gomez K, Monahan PE, Szafranski K, Zhang X, et al. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B. Haemophilia. 2024. doi:10.1111/hae.14882
BibTeX
@article{Klamroth2024,
author = {Klamroth, Robert and Bonner, Ashley and Gomez, Keith and Monahan, Paul E and Szafranski, Kirk and Zhang, Xiang and Walsh, Sarah and Wang, Di and Yan, Songkai},
title = {Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.14882}
}
EUVIMED